Alkermes (ALKS) Cash from Investing Activities (2010 - 2026)
Alkermes' (ALKS) quarterly Cash from Investing Activities came in at -$2.1 billion in Q1 2026, down 22919.16% year-on-year from N/an in Q1 2025, and down 744.34% on a QoQ basis from $322.3 million in Q4 2025.
Alkermes (ALKS) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Cash from Investing Activities data on file, last reported at -$2.1 billion in Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 22919.16% year-over-year to -$2.1 billion in Q1 2026; TTM through Mar 2026 was -$1.8 billion, a 2776.24% decrease from a year earlier, with the FY2025 full-year figure at $295.5 million, up 365.48% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$2.1 billion, down from $322.3 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for ALKS reached as high as $322.3 million in Q4 2025 and fell as low as -$2.1 billion in Q1 2026.
- Historically, Cash from Investing Activities has averaged -$112.0 million across 5 years, with a median of -$13.9 million in 2024.
- Across the five-year window, Cash from Investing Activities jumped 3838.54% in 2022 and sank 22919.16% in 2026, its largest moves.
- Year by year, Cash from Investing Activities stood at $27.7 million in 2022, then slumped by 175.64% to -$21.0 million in 2023, then surged by 33.87% to -$13.9 million in 2024, then surged by 2423.21% to $322.3 million in 2025, then tumbled by 744.34% to -$2.1 billion in 2026.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$2.1 billion in Q1 2026, $322.3 million in Q4 2025, and -$6.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 743.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | -2.08 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.08 Bn |
| Mar 31, 2026 | -2.08 Bn |
| Dec 31, 2025 | 322.35 Mn |
| Dec 31, 2025 | 322.35 Mn |
| Sep 30, 2025 | -6.74 Mn |
| Sep 30, 2025 | -6.74 Mn |
| Jun 30, 2025 | -29.21 Mn |
| Jun 30, 2025 | -29.21 Mn |
| Mar 31, 2025 | 9.10 Mn |
| Mar 31, 2025 | 9.10 Mn |
| Dec 31, 2024 | -13.88 Mn |
| Dec 31, 2024 | -13.88 Mn |
| Sep 30, 2024 | -109.33 Mn |
| Sep 30, 2024 | -109.33 Mn |
| Jun 30, 2024 | 51.85 Mn |
| Jun 30, 2024 | 51.85 Mn |
| Mar 31, 2024 | -39.95 Mn |
| Mar 31, 2024 | -39.95 Mn |
| Dec 31, 2023 | -20.98 Mn |
| Dec 31, 2023 | -20.98 Mn |